Background Image
Menu

Latest News

Monica Healthcare secures N'Tech grant

11 April 2014

Monica Healthcare secures N'Tech grant

A University of Nottingham spin-out has been awarded a grant of more than £250,000 to support a further £1m investment into the business. Monica Healthcare, based at BioCity, is led by Dr Carl Barratt. The company has developed a foetal and maternal monitor, which is...

Oxford Cryosystems helps push the boundaries of the known universe

8 April 2014

Oxford Cryosystems helps push the boundaries of the known universe

Senior management from Oxfordshire-based business Oxford Cryosystems are celebrating their involvement in a global project to create what will eventually become the largest and most sensitive radio telescope on earth. Directors Richard Glazer and Alex Renshaw joined a delegation...

Onwards and upwards for BWB Birmingham

1 April 2014

Onwards and upwards for BWB Birmingham

2013/14 has been a truly remarkable year for BWB’s Birmingham office. Fuelled by successful appointments on a spate of regionally significant projects such as Severn Trent Water’s HQ in Coventry and Resorts World at the NEC, staff numbers in the office is expected to...

Sprue Aegis plc (“Sprue”) and Intamac to launch connected safety solution

27 March 2014

Sprue Aegis plc (“Sprue”) and Intamac to launch connected safety solution

Intamac Systems Limited announces a new 3 year partnership agreement with Sprue, one of Europe’s leading suppliers of home safety products including smoke and carbon monoxide alarms sold under the FireAngel brand. Under the partnership, Sprue will launch an internet...

No Photo

19 March 2014

Biofortuna receives FDA clearance of its SSPGo™ line of HLA molecular diagnostic freeze-dried kits

Biofortuna, a UK based molecular diagnostics company with proprietary freeze drying (lyophilizing) technology, has received FDA 510K clearance for its line of SSPGo™ HLA PCR kits. The SSPGo HLA Typing Kits are qualitative DNA-based kits for determining HLA alleles in low...

New England Biolabs® announces supply agreement with Lumora

7 March 2014

New England Biolabs® announces supply agreement with Lumora

5th March, 2014 (Ipswich, MA, USA) New England Biolabs, Inc. (NEB®), a world leader in the production and supply of recombinant enzymes and related reagents for the life science industry, has strengthened its position as a key supplier to the fast-growing molecular...

Prime Minister David Cameron visits portfolio company Oxford Cryosystems

26 February 2014

Prime Minister David Cameron visits portfolio company Oxford Cryosystems

The Prime Minister, David Cameron, recently visited Oxford Cryosystems in Long Hanborough to meet executives and staff from the market-leading manufacturer of specialist scientific instrumentation and software. During his visit, Mr Cameron toured the production site with...

Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding

29 January 2014

Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding

Portfolio company Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, announces that the European Union has awarded a €2.26 million Framework 7 grant to a consortium of seven partners...

Michelson Diagnostics announces £1.98 million financing

13 January 2014

Michelson Diagnostics announces £1.98 million financing

Portfolio company Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, is delighted to announce the first closing of its Series A2 Financing. The round, which was oversubscribed, raised...

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia in $1 Billion Oncology Investment Alliance

11 December 2013

Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia in $1 Billion Oncology Investment Alliance

OXFORD, UK and BERLIN CHEMIE/MENARINI, GERMANY – 9th December 2013 – Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical...